Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: A Children's Oncology Group study

Blood

Volumn 108, Issue 2, 2006, Pages 711-717

  Bhojwani, Deepa ^b   Kang, Huining ^b   Moskowitz, Naomi P ^b   Min, Dong Joon ^b   Lee, Hokyung ^b   Potter, Jeffrey W ^b   Davidson, George ^b   Willman, Cheryl L ^b   Borowitz, Michael J ^b   Belitskaya Levy, Ilana ^b   Hunger, Stephen P ^b   Raetz, Elizabeth A ^b   Carroll, William L ^a  

^a NEW YORK UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BIOLOGY; CANCER RELAPSE; CANCER RESEARCH; CARCINOGENESIS; CELL CYCLE REGULATION; CLONOGENESIS; CONTROLLED STUDY; DNA REPAIR; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; ONCOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STATISTICAL ANALYSIS; UPREGULATION;

EID: 33745940511     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-02-002824     Document Type: Article

References (35)

1. Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse - the Children's Cancer Group Experience. Cancer. 1998;82:1387-1395.
2. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131:579-587.
3. Lawson SE, Harrison G, Richards S, et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study. Br J Haematol. 2000;108:531-543.
4. Roy A, Cargill A, Love S, et al. Outcome after first relapse in childhood acute lymphoblastic leukaemia: lessons from the United Kingdom R2 trial. Br J Haematol. 2005;130:67-75.
5. Ebert BL, Golub TR. Genomic approaches to hematologic malignancies. Blood. 2004;104:923-932.
6. Carroll WL, Bhojwani D, Min DJ, Moskowitz N, Raetz EA. Childhood acute lymphoblastic leukemia in the age of genomics. Pediatr Blood Cancer. 2005;46:560-578.
7. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249-264.
8. Davidson G, Hendrickson B, Johnson D, Meyers C, Wylie B. Knowledge mining with VxInsight: discovery through interaction. J of Intell Information Syst. 1998;11:259-285.
9. Davidson G, Wylie B, Boyack K. Cluster stability and the use of noise in interpretation of clustering. In: Andrews K, Roth S, Wong P eds. 7th IEEE Symposium on Information Visualization (InfoVis 2001). San Diego, CA; 2001:23-30.
10. Kim SK, Lund J, Kiraly M, et al. A gene expression map for Caenorhabditis elegans. Science. 2001;293:2087-2092.
11. Werner-Washburne M, Wylie B, Boyack K, et al. Comparative analysis of multiple genome-scale data sets. Genome Res. 2002;12:1564-1573.
12. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, et al. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses. 1995;45:486-490.
13. Hochberg Y. A sharper Bonferroni for multiple significance testing. Biometrika. 1988;75:800-803.
14. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116-5121.
15. Nakao M, Yokota S, Horiike S, et al. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia. 1996;10: 1463-1470.
16. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46-54.
17. Hamid T, Kakar SS. PTTG/securin activates expression of p53 and modulates its function. Mol Cancer. 2004;3:18.
18. Solbach C, Roller M, Peters S, Nicoletti M, Kaufmann M, Knecht R. Pituitary tumor-transforming gene (PTTG): a novel target for anti-tumor therapy. Anticancer Res. 2005;25:121-125.
19. Skotheim RI, Kallioniemi A, Bjerkhagen B, et al. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol. 2003;21:4586-4591.
20. Yuan J, Yan R, Kramer A, et al. Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene. 2004;23:5843-5852.
21. Hiraoka A, Sugimura A, Seki T, et al. Cloning, expression, and characterization of a cDNA encoding a novel human growth factor for primitive hematopoietic progenitor cells. Proc Natl Acad Sci U S A. 1997;94:7577-7582.
22. van Doorn R, Zoutman WH, Dijkman R, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol. 2005;23:3886-3896.
23. Ansell SM, Arendt BK, Grote DM, et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia. 2004;18:616-623.
24. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
25. Callagy G, Pharoah P, Chin SF, et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol. 2005;205:388-396.
26. Mio H, Kagami N, Yokokawa S, et al. Isolation and characterization of a cDNA for human mouse, and rat full-length stem cell growth factor, a new member of C-type lectin superfamily. Biochem Biophys Res Commun. 1998;249:124-130.
27. Sauerbrey A, Hafer R, Zintl F, Volm M. Analysis of cyclin D1 in de novo and relapsed childhood acute lymphoblastic leukemia. Anticancer Res. 1999;19:645-649.
28. Matherly LH, Taub JW, Ravindranath Y, et al. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood. 1995;85:500-509.
29. Gorlick R, Goker E, Trippett T, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood. 1997;89:1013-1018.
30. Prokop A, Wieder T, Sturm I, et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia. 2000;14:1606-1613.
31. Carter TL, Reaman GH, Kees UR. INK4A/ARF deletions are acquired at relapse in childhood acute lymphoblastic leukaemia: a paired study on 25 patients using real-time polymerase chain reaction. Br J Haematol. 2001;113:323-328.
32. Maloney KW, McGavran L, Odom LF, Hunger SP. Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood. 1999;93:2380-2385.
33. Beesley AH, Cummings AJ, Freitas JR, et al. The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure. Br J Haematol. 2005;131:447-456.
34. Staber PB, Linkesch W, Zauner D, et al. Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene. 2004;23:894-904.
35. Zuna J, Ford AM, Peham M, et al. TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin Cancer Res. 2004;10:5355-5360.